This Project Grant award of $1,188,167 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under CFDA 93.847, the Diabetes, Digestive, and Kidney Diseases Extramural Research program, supports research to develop inhibitors of the sphingosine 1-phosphate (S1P) signaling pathway as potential therapies for chronic kidney disease (CKD). The primary awardee, Virginia Polytechnic Institute & State University (Virginia Tech), will work to improve the oral...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1,145,486 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Makscientific LLC, a for-profit research and development company located in Burlington, MA. The grant supports the development of novel peripherally acting CB1 neutral antagonists for treating diabetic kidney disease (DKD). The project aims to design and synthesize improved analogs of...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) is funding research to develop a therapeutic approach using dicarboxylic acids (DCAs) to prevent and treat acute kidney injury (AKI) and limit progression to chronic kidney disease (CKD). The $645,599 award to the University of Pittsburgh is supporting preclinical studies in animal models...
This $400,000 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to understand the earliest events in podocyte injury in collagen IV nephropathies. The goal is to investigate how processing of mutant collagen IV proteins injures podocytes at early stages, leading to chronic kidney disease and renal failure. The research uses...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $436,277 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of Delaware. The grant titled "NEPHROGENESIS ON A CHIP: AN SIMPLE MODULAR PLATFORM TO SPATIALLY PATTERN EXTRACELLULAR MATRIX, STROMAL CELLS, AND SOLUBLE FACTORS" aims to develop an easy-to-use 3D in vitro model of the developing nephron that allows spatial patterning...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $499,890 Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to Pavaj Vascular Corporation to develop a novel therapy to prevent arteriovenous fistula (AVF) venous stenosis, a common complication in end-stage kidney disease patients requiring hemodialysis. The funding will support two main goals: 1) evaluating the stability and biocompatibility of a nanoparticle-based...
This $820,119 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research focused on elucidating the mechanobiological functions of novel cytoskeletal structures in podocytes to reveal new therapeutic opportunities for kidney glomerular diseases. The primary research aims to better understand the mechanisms underlying podocyte homeostasis,...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is funding the development and validation of an allysine-targeted positron emission tomography (PET) probe to noninvasively quantify renal fibrosis. The $1,447,749 award to The General Hospital Corporation (doing business as Massachusetts General Hospital) will support additional IND-enabling...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $349,325 Project Grant under CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research to Regennova, Inc., a small disadvantaged business in Durham, North Carolina. The grant supports the development of an orally-available, effective, and well-tolerated drug to treat autosomal dominant polycystic kidney disease (ADPKD), which affects over 350,000 Americans. The project aims to create and...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $223,918 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of Oklahoma Health Sciences Center. The purpose of this 20-month grant, awarded on September 28, 2024, is to study niche filling as a means to achieve long-term, kidney-specific depletion of resident macrophages in order to slow the progression of autosomal dominant polycystic...
This $675,480 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research to develop a novel therapeutic compound for treating chronic kidney disease (CKD). The awardee, Fibrotherapeutics Inc., is conducting preclinical studies to evaluate the efficacy, safety, and therapeutic index of a modified, water-soluble, orally-active peptide derived from the caveolin-1 scaffolding domain (CSD). The research aims to demonstrate that this lead compound can inhibit kidney fibrosis, vascular leakage, and functional deficits by over 50% in mouse models of CKD. Successful completion of these studies by the award's end date of December 31, 2025 would advance this potential therapeutic towards further development and clinical testing.